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Abstract
Background: Patients with Addison’s disease (AD) in Scandinavia have an increased risk for premature death due to
cardiovascular disease (CVD). Serum lipids are important risk factors for CVD and vascular mortality. Replacement doses of
hydrocortisone have historically been higher in Sweden than South Africa. The primary aim was to study the lipid profiles in
a large group of patients with AD with the hypothesis that the lipid profile in patients in Sweden would be worse than in
South Africa.
Methods: In a cross-sectional study, 110 patients with AD (55 from South Africa, 55 from Sweden) matched for age, gender,
ethnicity and BMI were studied. Anthropometric measures, blood pressure, lipids, highly sensitive C-reactive protein (hs-
CRP) and adiponectin were studied.
Results: All patients were Caucasian and the majority were women N=36 (65.5%). Mean (standard deviation; SD) ages of
the Swedish and South African patients were 52.9 (13.0) and 52.6 (14.4) years and BMI 25.3 (3.2) and 25.8 (4.1) kg/m2,
respectively. The mean total daily hydrocortisone dose was greater in the Swedish patients than the South African patients,
[33.0 (8.1) versus 24.3 (8.0) mg; p,0.0001]. South African patients had higher median (interquartilerange; IQR) triglycerides
(TG) [1.59 (1.1–2.46) versus 0.96 (0.74–1.6) mmol/l; p,0.001], total cholesterol (TC) [6.02(1.50) versus 5.13 (0.87) mmol/l; p,
0.001], LDL-C [4.43 (1.44) versus 2.75 (0.80) mmol/l; p,0.001] and median hs-CRP [2.15 (0.93–5.45) versus 0.99 (0.57–2.10)
mg/L; p,0.003] and lower HDL-C [0.80 (0.40) versus 1.86 (0.46) mmol/l; p,0.001] than the Swedish patients. Approximately
20% of the patients in both cohorts had hypertension and diabetes mellitus.
Conclusions: South African patients with AD have worse lipid profiles and higher hs-CRP compared to their matched
Swedish patients, despite lower doses of hydrocortisone. It is uncertain at this time whether these are due to genetic or
environmental factors.
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Introduction
There is a more than two-fold increase in relative risk of death
in Swedish patients with Addison’s disease (AD), compared to the
background population, predominantly due to cardiovascular
disease (CVD) [1,2], with the greatest number of deaths from
ischaemic heart disease followed by cerebrovascular disease [1]. In
a diverse population of South African patients with AD, we
previously demonstrated that AD patients had a wide range of
cardiovascular risk factors including elevated triglycerides, lower
high density lipoprotein cholesterol (HDL-C) and elevated high
sensitivity C-reactive protein (hs-CRP) than healthy control
subjects [3]. Thus it is plausible that the accelerated CVD
mortality among AD may be the result of several coexisting
abnormal CVD risk factors. AD per se may have contributed to
the excess mortality, although inadequate or supra-physiological
glucocorticoid (GC) replacement therapy may have conferred
adverse effects on CVD risk factors [4]. On the other hand,
Norwegian patients with AD younger than 40 years, particularly
males, were at risk for premature death due to infections, sudden
death and acute adrenal failure [5].
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Glucocorticoid (GC) excess has an important impact on
cardiovascular risk factors [4]. In a large study of patients with
hypopituitarism, a total daily replacement dose of hydrocortisone
of $20 mg was associated with an increase in CVD risk factors, as
evidenced by increased waist circumference, total cholesterol (TC)
and low-density lipoprotein cholesterol (LDL-C) and triglycerides
(TG) [6].
Unlike studies of hypopituitarism associated with secondary
adrenal insufficiency, there is a paucity of studies evaluating the
CVD risk in primary adrenal insufficiency. In a study of 38 AD
patients, Giordano et al showed a higher proportion of patients
who were hypercholesterolaemic and hypertriglyceridaemic than
their matched controls [7]. Leelarathna and co-workers found a
significant proportion of AD patients with dyslipidaemia [8],
whereas Gurnell et al reported normal lipid profiles in 100
patients with AD [9]. Since the conventional GC replacement
regimen often exceeds the normal endogenous cortisol production
rate, it could be expected that using supra-physiological doses of
GCs may increase the prevalence of risk factors for CVD [10].
Indeed, cardiovascular risk factors in adrenal insufficiency have
shown to improve with a more physiological circadian cortisol
profile during hydrocortisone replacement therapy, suggesting that
not only the actual daily dose and total exposure are important,
but also the profile of exposure [11].
Animal studies have shown that supra-physiological doses of
GCs may raise TG, TC, LDL-C and high-density lipoprotein
cholesterol (HDL-C) concentrations [12,13]. GCs reduce hepatic
lipase activity, which reduces the metabolism of HDL2 to HDL3,
resulting in increased HDL-C concentration. Apoprotein A1 has
also been found to increase in response to GCs, resulting in
increased HDL-C [14]. GCs have also been reported to reduce
lipoprotein lipase activity resulting in an increase in TG [15].
Down regulation of LDL receptors may account for the rise in
LDL and TC [16]. Furthermore, diseases coexisting with AD,
such as hypothyroidism and diabetes mellitus (DM) could also
contribute to alterations in lipid concentrations and increase in risk
for CVD [17].
Lipid patterns differ amongst countries and changes in time
have also been observed. Sweden and South Africa are developed
and developing countries, respectively and therefore geographical
regions may influence lipid profiles and blood pressure of AD
patients. Studies from Sweden have shown a decrease in the
prevalence of hypercholesterolaemia (total cholesterol and triglyc-
erides) in the general population [18–20], but those with basic
education and living in rural areas had higher risk of developing
hypercholesterolemia and hypertriglyceridemia, compared to
those with higher education and living in urban areas [20].
Reliable data reflecting CVD prevalence in Africa are scarce.
Nevertheless, some data show an increase in the incidence of CVD
in Africa [21], explained by traditional CVD risk factors [22].
Our previous studies and personal communication indicate that
patients with AD are likely to be treated with lower doses of GCs
in South Africa, compared with Sweden [11] [23]. As Swedish
patients with AD have been shown to have double the relative risk
of death, predominantly due to cardiovascular disease [1,2], and
South African patients have an adverse lipid profile we wished to
compare cardiovascular risk factors in matched Swedish and
South African AD patients for age, gender, ethnicity and body
mass index to determine whether glucocorticoid dose and
geographical areas play a role in influencing cardiovascular risk
in these patients. The primary aim of this study was to compare
plasma lipids in patients with AD in South Africa and Sweden.
Secondary objectives were to compare markers of cardiovascular
inflammation.
Patients and Methods
The Research and Ethics committee of the University of Cape
Town and local research ethics committees in South Africa
approved this study. These were from the respective research and
ethics committees overseeing the various faculties of health
sciences including the Nelson Mandela School of Medicine,
University of Kwazulu-Natal, University of Stellenbosch, Univer-
sity of the Free State, University of Pretoria and the University of
Witwatersrand. The Regional Ethical Review Board at the
University of Gothenburg approved the study in Sweden. All
patients received written and oral information and gave written
informed consent prior to being enrolled in the study.
Patients
AD patients $18 years of age in the western part of Sweden
were invited to participate. Enrolment took place in Gothenburg
between 2005 and 2008. The South African AD patients were
selected from the South African Addison’s disease study database,
a cohort which enrolled patients between 2005 and 2010, the
results of which have been published previously [24]. After
enrolling the Swedish patients, patients matched for age, gender,
BMI and ethnicity from the South African database were
included.
Clinical and demographic data
The Swedish cohort included only white patients; hence the
ethnicity was restricted to white patients in the South African
cohort. Disease duration, history of CVD risk factors including
hypertension, diabetes mellitus (DM), lipid-lowering therapy and
smoking were recorded. The doses of hydrocortisone and
fludrocortisone were documented, in addition confirmation that
the doses had not been altered for at least three months, prior to
being enrolled. Clinical examination included blood pressure,
body mass index (BMI) and confirmation that they were clinically
stable without a superimposed acute illness.
Biochemical assays for lipids and markers of CVD
Lipid assays. Lipid assays were conducted in two separate
laboratories; the Gothenburg subjects were analysed by the
Division of Clinical Chemistry, Sahlgrenska University Hospital,
Gothenburg, while the South African subjects’ sera were analysed
in the Division of Lipidology at the University of Cape Town.
Both laboratories comply with Precinorm (Boehringer Mannheim
GmbH, Mannheim, Germany), which has international consensus
values for plasma lipids, ensuring that magnitude of the potential
difference is acceptable at 10%. In the case of South African
patients, the assays for TG and TC were performed using
commercially available enzymatic kits, standard curves and
calibrators. The respective kits for TG, TC, were KAT
(Roodepoort, Gauteng, South Africa) and HDL-C was determined
using the first step in the Gidez assay, which yields HDL-C in the
supernatant of a heparin-Mn precipitation of apolipoprotein B-
containing lipoproteins [25]. The inter-assay coefficient of
variation (CV) for TC was 2.2% at 2.4 mmol/L and 1.8% at
4.99 mmol/L, for TG 2.8% at 1.2 mmol/L and 2.2% at
2.2 mmol/L, for HDL-C 2.3% at 1.4 mmol/L and 2.3% at
0.8 mmol/L and LDL-C was calculated by the Friedewald
equation: LDL-C = TC – HDLC – (TG/2.18), provided TG
,4.5 mmol/L [26] with a CV of 4.2%.
In the case of Swedish patients, TC, TG, HDL-C and LDL-C
(LDL-C from October 2007, 7 patients) were determined by
enzymatic techniques (Modular P800, Roche Diagnostics, GmbH,
Mannheim, Germany). The within-assay CV for TC, TG, HDL-C
Lipids in Patients with Addison’s Disease
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and LDL-C determinations was 3% (at 4 and 6 mmol/L), 4% (at 1
and 2 mmol/L), 5% (at 1 and 2 mmol/L) and 4% (at 2 and
5 mmol/L) respectively. The LDL-C was calculated according to
Friedewald’s formula prior to October 2007 (45 patients) and if
TG values ,4.5 mmol/L [26].
Highly sensitive C-reactive protein (hs-CRP) and
Adiponectin. For both the South African and Swedish patients,
hs-CRP and adiponectin were measured in the same laboratory at
the Division of Clinical Chemistry, Sahlgrenska University
Hospital, Gothenburg.
hs-CRP was measured by using highly sensitive particle
immuno-turbidometric assay (Roche Diagnostics, GmbH, Man-
nheim, Germany), with a CV of 4% and 3% at serum
concentrations of 1 and 15 mg/L, respectively. hs-CRP was
corrected for SA patients after excluding a single outlier of 77 mg/
L from the analysis. Adiponectin was measured by using ELISA kit
(Millepore Corp., Billerica, MA, USA) with a CV of 11% at
2.1 mg/L and 7% at both 11.5 mg/L and 22 mg/L.
The thyroid stimulation hormone (TSH) was measured in
Sweden for the Swedish patients, using the Roche Modular/Cobas
(Rotkreuz, Switzerland) analyser and in South Africa, the Abbott
Architect (Illinois USA) for the SA patients was used. The
reference intervals for TSH in the South African and Swedish
laboratories were 0.35–4.94 mIU/L and 0.27–4.2 mIU/L, re-
spectively.
Statistical methods. The Shapiro-Wilk test was used to
determine the distribution of each variable and the chi-squared
test was used to assess significance for proportions. Normally
distributed variables were compared using independent t-tests.
Assessment for significant differences in non-parametric data was
performed using the Mann-Whitney test. Statistical significance
was reached when the p-value ,0.05. 95% confidence intervals
were constructed using the Wald approximation. Statistical
software IBMH SPSSH 17.0, Somers, NY 10589 USA was used.
Results
The Swedish and South African patients were well-matched
with respect to age and BMI (Table 1). Both cohorts were white.
Total daily hydrocortisone dose was higher among the Swedish
patients (33 mg, range 10–50) than the South African patients
(24.3 mg, range 5–40); p,0.001. Patient characteristics are
demonstrated in Table 1.
All the patients in the South African cohort were assessed for
21-hydroxylase autoantibodies with the majority of patients (76%)
being positive, 1 patient had tuberculosis and the remainder were
thought to have idiopathic AD. In the Swedish cohort, 73% were
tested for 21-hydoxylase autoantibodies of whom, 83% had
positive autoantibodies, and in the remainder the aetiology was
idiopathic. Approximately 20% of the patients in both cohorts had
hypertension and diabetes mellitus.
Lipids, hs-CRP and adiponectin
The concentrations of TC, TG and LDL-C were lower, but
HDL-C was higher, in the Swedish patients, compared with the
South African patients. The hs-CRP was reduced in the Swedish
group, compared to the South-African patients (Table 2).
Adiponectin did not differ between the cohorts. The differences
in lipids, lipoproteins and hs-CRP remained even after removing
patients on lipid-lowering therapy and patients with diabetes
mellitus from the statistical analysis (data not shown). A large
proportion of the South African patients and to a lesser extent the
Swedish patients, had unfavourable lipid levels exceeding the
recommended targets defined by the NCEP ATP III guidelines
(Figure 1) [27]. The relative proportions of Swedish patients,
compared with South African patients exceeding a TC .
5.0 mmol/L, LDL-C .3.0 mmol/L, TG .1.7 mmol/L and a
HDL-C ,1.0 mmol/L were 59.3% vs. 72.2%; (p = 0.160), 35.8
vs. 78.6%; (p,0.0001), 22.6% vs. 43.4%; (p = 0.02) and 1.9% vs.
77.8%; (p,0.0001), respectively.
Discussion
South African AD patients exhibit a more atherogenic profile
with higher LDL-C, TG, and lower HDL-C, and elevated hs-CRP
concentrations, despite being exposed to lower daily hydrocorti-
sone doses, in comparison with Swedish AD patients. Our findings
collectively suggest that the CVD risk is markedly elevated, as
reported with AD [1], albeit that South African AD patients on
lower doses of hydrocortisone, have greater risk than Swedish AD
patients.
While the increased HDL-C among Swedish patients could be
explained on the basis of an elevated cortisol exposure [14], other
Table 1. Clinical characteristics of patients with Addison’s disease from Sweden (SE) and South Africa (SA).
Characteristics SE SA p-value
N 55 55
Age (SD) years* 52.9 (13.0) 52.6 (14.4) 0.897
Female N(%) 36 (65.5) 36 (65.5) -
BMI (SD) kg/m2* 25.3 (3.2) 25.8 (4.1) 0.414
Hypertension N(%) 10 (18.2) 12 (21.8) 0.565
Diabetes N(%) 10(18.2) 12 (21.8) 0.599
Lipid lowering therapy N(%) 9 (16.4) 11 (20) 0.757
Smokers N(%) 4 (7.3) 4 (7.3) 0.632
Duration of disease (SD) years* 17.3 (11.3) 14.2 (12.0) 0.173
TSH mU/L * 2.57 (2.5) 1.97 (2.7) #
Hydrocortisone (SD) mg* 33.0 (8.14) 24.3 (8.0) 0.001
Data presented as: * mean (standard deviation), N: number.
#: Not done as the method and reference ranges differ.
doi:10.1371/journal.pone.0090768.t001
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health promoting factors in the Swedish population could be
accounting for this. Poor lifestyle may significantly contribute to
dyslipidaemia and cardiovascular risk among South Africans.
Environmental and economic factors can impact lipids with Reddy
et al, predicting a rise of early-onset vascular events and the
burden of CVD in the Third World [28]. The Scandinavian
countries by comparison, have enjoyed long-standing emphasis on
reducing cardiovascular risk factors. The 4S study has been pivotal
in raising awareness on detection of lipid abnormalities in
Northern Europe [29] and could have influenced the Swedish
population favourably. It is conceivable that in First World
countries, greater willingness exists among the public to pursue
physical activity and healthier food options.
Neither ethnicity, nor BMI differed between these two groups of
AD patients due to the matching of the two groups. The patients
demonstrated an increased weight in both groups, but data on
Figure 1. Bar chart showing the comparative proportions and 95% confidence intervals of Swedish and South African patients
exceeding the recommended targets for TC ,5.0 mmol/L; (p =0.160), LDL-C ,3.0 mmol/L; (p,0.0001), TG ,1.7 mmol/L; (p =0.02)
and failing to achieve an HDL-C .1.0 mmol/L; (p,0.0001), according to ATP III NCEP (Adult Treatment Panel III, National
Cholesterol Education Programme) recommendations.
doi:10.1371/journal.pone.0090768.g001




TG (IQR) mmol/LW 0.96 (0.74–1.6) 1.59 (1.1–2.46) ,0.001
TC (SD) mmol/L* 5.13 (0.87) 6.02 (1.50) ,0.001
HDL-C (SD) mmol/L* 1.86 (0.46) 0.80 (0.40) ,0.001
LDL-C (SD) mmol/L* 2.75 (0.80) 4.43 (1.44) ,0.001
hs-CRP (IQR) mg/LW 0.99 (0.57–2.10) 2.15 (0.93–5.45) 0.003
Adiponectin (IQR) mg/LW 12.60 (8.18–17.9) 13.50 (8.10–19.6) 0.34
Data presented as: * mean (standard deviation) W median (interquartile range).
doi:10.1371/journal.pone.0090768.t002
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waist circumference, dietary habits, alcohol consumption and of
physical activity were not available. The extent, to which life-style,
socio-economic, educational attainment and levels of health-care
factors contributed to these differences found between the cohorts,
is uncertain.
Both uncontrolled diabetes and hypothyroidism are known to
adversely influence the blood lipid profile, but the differences
between the cohorts in lipid profiles persisted, even after exclusion
of patients with diabetes mellitus. Moreover, the majority of the
Swedish and South African patients were euthyroid. Although the
lipid profile was more favourable in the Swedish group, the TSH
was numerically higher than the South African group, indicating
the difference in lipids and lipoproteins between the groups is not
explained by the difference in thyroid functions.
There could also be some genetic predisposition, either a
favourable or unfavourable variation accounting for the differ-
ences between these two distinct geographical groups. Genetic
defects for example, Apo E2/E2 status, which is known to occur in
1:50 of the general population, can produce elevated TG levels
[30]. Genetic deficiencies of lipoprotein lipase may also produce
elevated TG levels, especially with excess hydrocortisone replace-
ment [31]. Our respective cohorts were not screened for these or
other genetic defects and are probably too small for genetic
variants to play a significant role.
hs-CRP is an acute phase reactant protein that is associated with
ischaemic vascular disease [32]. The influence of dehydroepian-
drosterone (DHEA) on hs-CRP in adrenal insufficiency has been
evaluated, but no change was found when DHEA was substituted,
albeit that the mean hs-CRP was normal at 1.4 mg/L [33]. In
addition our cohorts were exclusively white, eliminating ethnicity
as a cause for the elevated hs-CRP.
It is intriguing that Nazmi et al, showed that poverty and socio-
economic factors may also account for a raised hs-CRP [34], and
it is entirely plausible that the lower socio- economic status that
exists in South Africa may contribute to the relative increase,
compared with the Swedish AD patients. Another possible
explanation for comparatively reduced hs-CRP in the Swedish
group is their higher hydrocortisone substitution doses as Short
term GC treatment has been shown to decrease hs-CRP [35]. hs-
CRP has also been shown to associate with abdominal obesity and
it is possible that the higher concentrations in the South African
cohort indicate that they harbour relatively more visceral fat with
insulin resistance and impaired glucose metabolism, but this is not
yet been tested. The similar concentrations of adiponectin in both
groups however, do not support a difference in insulin sensitivity.
Although CRP is reduced by statins, the difference in hs-CRP in
the 2 cohorts remained significant when those receiving lipid-
lowering therapy were excluded. The markedly raised hs-CRP in
the South African cohort is of concern and should be an important
impetus to modify, CVD risk factors aggressively in this group.
There is no consensus on the appropriate daily hydrocortisone
doses in AD patients. Based on the daily cortisol production rate in
healthy adults and the fact that doses below 20 mg per day have
approximately 90% bioavailability, current doses can be consid-
ered too high in most patients. Doses above or equal to 20 mg
have been associated with adverse metabolic outcome in
hypopituitary patients [36]. There may be a negative association
between dose exposure and bone mineral density [37] and lower
doses may be associated with better health related quality of life
[6,38,39]. Chronic over-replacement with GCs could have
influenced the cardiovascular profile in the Swedish patients and
the non-physiological replacement therapy may have potentially
influenced both groups negatively. It is conceivable that the
differences in lipid profiles may have been even greater had the
hydrocortisone replacement been lower in the Swedish AD
patients.
This study has a number of limitations. The study was designed
to include fasted participants with their hydrocortisone tablet
taken prior to sampling, but this could not be verified in the South
African cohort. It is possible that the TG concentrations in the
South African cohort may have been taken in the post-prandial
state, accounting for the relatively higher TG concentrations.
Assessment of glucose tolerance in relation to hydrocortisone
doses, by performing oral glucose tolerance tests may have
provided insights into the aetiology of the relatively high TG
concentrations in both cohorts. Anthropometric measurements
such as waist circumference to estimate the visceral fat could have
complemented our understanding of the hypertriglyceridaemia.
Important lifestyle factors such as diet, alcohol consumption and
physical activity were not evaluated in this study. Moreover, the
interpretation of the data would have been strengthened by
matched healthy controls for both cohorts to determine the extent
to which patients differed from their background populations.
Despite our observed adverse lipid profiles and cardiovascular risk
factors particularly in the South African cohort, it remains
uncertain as to whether these are due to AD per se or its
management.
While we have identified that South African patients, compared
with Swedes with AD have higher risk using cardiovascular risk
factors as a crude assessment, accurate mortality data in South
Africa unlike Sweden would be very difficult to generate. This
study should prompt further research into the genetic profiles of
these patients, in order to explain our observed vast differences in
cardiovascular risk factors in these cohorts.
Conclusions
Both groups of patients with AD have increased CVD risk, but
the South African group exhibits a more atherogenic profile with
higher TC, LDL-C, hs-CRP and lower HDL-C compared with
the Swedish group, despite the former patient group being
replaced on lower doses of hydrocortisone. Although the higher
doses of hydrocortisone replacement in the Swedish group could
have aggravated the CVD risk profile, the relatively lower doses of
hydrocortisone replacement in the South African patient group
did not appear to mitigate against CVD risk factors. Environ-
mental factors are likely more important in modifying CVD risk
factors associated with AD than hydrocortisone dose. Neverthe-
less, we believe it is critical to treat hypertension, diabetes and lipid
abnormalities, while encouraging smoking cessation in this group
of AD patients where cardiovascular risk factors are prevalent.
Overall, our analysis reveals that despite higher doses of
hydrocortisone replacement, the cardiovascular profile in Sweden
is far more favourable than in South Africa, where lower doses of
hydrocortisone are used.
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